Published on 27 Mar 2023 on Simply Wall St. via Yahoo Finance

When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. The US$151m market-cap company posted a loss in its most recent financial year of US$34m and a latest trailing-twelve-month loss of US$28m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which Citius Pharmaceuticals will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

View our latest analysis for Citius Pharmaceuticals

According to some industry analysts covering Citius Pharmaceuticals, breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$56m in 2025. The company is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 66% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.